

GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.in.net Website: www.gtbl.in

Statement of Unaudited Results for the quarter ended and nine months ended December 31, 2018

(Amount in INR Lakhs)


Sr. No.	PARTICULARS	Quarter Ended			Nine Month Ended		Year Ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income from operations	980.79	1,050.57	983.24	3,069.32	2,884.59	3,879.99
II	Other income	11.69	8.65	0.76	30.64	7.24	16.51
III	Total Income (I+II)	992.48	1,059.21	984.00	3,099.96	2,891.83	3,896.50
IV	Expenditure						
	(a) Cost of raw material consumed	8.68	8.30	9.49	25.68	28.32	37.97
	(b) Purchases of stock-in-trade	-0.00	51.35	62.76	96.99	154.55	177.37
	(c) Employee benefits expense	124.17	142.30	104.49	388.08	332.59	445.84
	(d) Finance Cost	6.09	4.45	4.88	13.24	31.08	41.77
	(e) Depreciation and Amortisation expenses	29.16	27.75	28.82	86.62	85.66	114.86
	(f) Other Expenses						
	i) Stores and spares	69.67	66.39	65.71	221.75	183.11	256.88
	ii) Power	388.47	384.47	375.27	1,155.40	1,124.12	1,485.85
	iii) Fuel	92.16	105.20	108.53	292.28	290.60	382.12
	iv) Water	17.97	18.04	16.71	54.47	48.80	64.81
	vi) Other expenditure	83.10	90.82	80.04	262.12	251.70	405.22
	Total Expenses	819.46	899.06	856.71	2,596.62	2,530.53	3,412.68
V	Profit (Loss) before Exceptional Items and Tax (III-IV)	173.02	160.15	127.29	503.34	361.29	483.81
VI	Exceptional Items						
VII	Profit (Loss) before Tax (V-VI)	173.02	160.15	127.29	503.34	361.29	483.81
VIII	Tax expenses						
	(a) Current Tax	52.50	26.50	23.80	115.00	71.40	102.99
	(b) Deferred Tax	-0.84	-	4.44	-0.84	2.85	-5.89
IX	Net Profit (Loss) after tax (VII-VIII)	121.36	133.65	99.05	389.18	287.04	386.72
X	Other Comprehensive Income						
	(i) Items that will not be reclassified to Profit or Loss	1.00	1.01	3.40	3.02	6.88	4.03
	(ii) Remeasurement of defined benefit plans;			-0.69		-1.40	
	(iii) Income Tax relating to items that will not be reclassified to Profit or Loss	-0.84	-	-	-0.84	-	-0.82
XI	Total Comprehensive Income for the period (IX+X)	121.53	134.66	101.76	391.37	292.52	389.93
XII	Paid-up equity share capital	726.40	726.40	726.40	726.40	726.40	726.40
XIII	Other Equity						484.53
XIV	Earnings Per Share (Basic and Diluted)	0.84	0.92	0.68	2.68	1.98	2.66

Notes:

- The financial results for the quarter ended December 31, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 08, 2019.
- The Company operates only in one Business Segment i.e. manufacturing drug intermediates for its own and on job work basis for others within India, hence does not have any reportable segments as per Indian Accounting Standard (Ind AS)-108 "Operating Segments".
- The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- In respect of Auditor's qualifications / Emphasis of Matter / observations in the Audit Report for the period ended December 31, 2018 that:
  - The outstanding balances as at December 31, 2018 in respect of certain balances of Advances given, liability for expenses, trade payables and creditors for capital expenditure are subject to confirmation from respective parties and consequential impact of reconciliation and adjustment arising there from in the statement, if any, is not ascertainable. The Management does not expect any material variation in the financial statements.
- Effective from 1st April, 2018, the Company has adopted Ind AS 115 'Revenue from Contract with Customers'. The adoption of this Standard did not have any impact on profits, retained earnings and earnings per share of the Company.
- Figures of previous periods/years' have been regrouped / rearranged, wherever considered necessary.

For Gujarat Themis Biosyn Ltd.

*(Signature)*  
Dr. Dinesh S. Patel  
Chairman



Place: Mumbai  
Date: February 08, 2019

**Independent Auditor's Review report on quarterly and year to date unaudited financial results of Gujarat Themis Biosyn Limited pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors  
Gujarat Themis Biosyn Limited

We have reviewed the accompanying statement of unaudited financial results of **Gujarat Themis Biosyn Limited** ('the Company') for the quarter ended December 31, 2018 and year to date unaudited financial results for the period from April 1, 2018 to December 31, 2018, attached herewith, being submitted by the Company pursuant to the requirement of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Basis of Qualified Conclusion:**

- a) The outstanding balances as at December 31, 2018 in respect of certain balances of Advances given, liability for expenses, trade payables and creditors for capital expenditure are subject to confirmation from respective parties and consequential impact of reconciliation and adjustment arising there from in the statement, if any, is not ascertainable.

Based on our review, conducted as stated above, except for the matters described in the Basis of Qualified Conclusion paragraph above, nothing has come to our attention that causes us to believe that the accompanying statement is prepared in accordance with applicable Indian Accounting Standards prescribed under section 133 of Companies Act 2013 read with rules issued thereunder and other recognised accounting practices and policies generally accepted in India, has not disclosed the information




required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For GMJ & Company**  
Chartered Accountants  
Firm Registration No:103429W



**CA Sanjeev Maheshwari**  
Partner  
Membership No.38755



Place : Mumbai  
Date : February 08, 2019